Sign Up to like & get
recommendations!
1
Published in 2022 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-022-00638-w
Abstract: 0123456789();: suggests that pembrolizumab can eradicate micrometastatic disease, which might ultimately translate into an overall survival benefit. Pembrolizumab was associated with mostly low-grade adverse events, with grade 3–4 toxicities in only 16% of patients (compared…
read more here.
Keywords:
pembrolizumab;
reduces recurrence;
pembrolizumab reduces;
stage melanoma ... See more keywords